HIV associated nephropathy epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2];Associate Editor(s)-in-Chief: Shakiba Hassanzadeh, MD [3]Krzysztof Wierzbicki M.D. [4]

Overview

HIV-associated nephropathy (HIVAN) is mostly seen in male patients and of African decent. The prevalence of HIVAN in the population of patients with African descent has been reported to be 3% to 12%.^[1]

Epidemiology

The prevalence of HIV-associated nephropathy (HIVAN) in the population of patients with African descent has been reported to be 3% to 12%.^[1]

Demographics

Age

The average age at which patients are affected with HIV-associated nephropathy has been reported to be around 40.8 years of age in a study.^[2]

Gender

HIV-associated nephropathy affects men more than women.^[2]

Race

HIVAN is mostly seen in patients of African descent.^[2]

References

↑ ^1.0 ^1.1 Menez S, Hanouneh M, McMahon BA, Fine DM, Atta MG (2018). “Pharmacotherapy and treatment options for HIV-associated nephropathy”. Expert Opin Pharmacother. 19 (1): 39–48. doi:10.1080/14656566.2017.1416099. PMC 6381591. PMID 29224373.
↑ ^2.0 ^2.1 ^2.2 Atta MG, Lucas GM, Fine DM (2008). “HIV-associated nephropathy: epidemiology, pathogenesis, diagnosis and management”. Expert Rev Anti Infect Ther. 6 (3): 365–71. doi:10.1586/14787210.6.3.365. PMID 18588500.

Template:WH Template:WS

[pmid29224373-1] 1.0 ^1.1 Menez S, Hanouneh M, McMahon BA, Fine DM, Atta MG (2018). “Pharmacotherapy and treatment options for HIV-associated nephropathy”. Expert Opin Pharmacother. 19 (1): 39–48. doi:10.1080/14656566.2017.1416099. PMC 6381591. PMID 29224373.

[pmid18588500-2] 2.0 ^2.1 ^2.2 Atta MG, Lucas GM, Fine DM (2008). “HIV-associated nephropathy: epidemiology, pathogenesis, diagnosis and management”. Expert Rev Anti Infect Ther. 6 (3): 365–71. doi:10.1586/14787210.6.3.365. PMID 18588500.

[1]

[2]